Journal
JOURNAL OF VIROLOGY
Volume 81, Issue 20, Pages 11016-11031Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01340-07
Keywords
-
Categories
Funding
- Intramural NIH HHS Funding Source: Medline
- NCI NIH HHS [N01-CO12400, N01CO12400] Funding Source: Medline
- NCRR NIH HHS [UL1 RR024143, RR024143] Funding Source: Medline
- NIAID NIH HHS [AI41534, U01 AI041534] Funding Source: Medline
Ask authors/readers for more resources
Three neutralizing monoclonal antibodies (MAbs), 2G12, 2F5, and 4E10, with activity in vitro and in vivo were administered in an open-label, nonrandomized, proof-of-concept study to attempt to prevent viral rebound after interruption of antiretroviral therapy (ART). Ten human immunodeficiency virus type I-infected individuals identified and treated with ART during acute and early infection were enrolled. The first six patients were administered 1.0 g of each of the three MAbs per infusion. The remaining four patients received 2G12 at 1.0 g/infusion and 2.0 g/infusion of 2175 and 4E10. The MAbs were well tolerated. Grade I post-partial thromboplastin time prolongations were noted. Viral rebound was observed in 8/10 subjects (28 to 73 days post-ART interruption), and 2/10 subjects remained aviremic over the course of the study. In seven of eight subjects with viral rebound, clear resistance to 2G12 emerged, whereas reductions in the susceptibilities of plasma-derived recombinant viruses to 2F5 and 4E10 were neither sustained nor consistently measured. Viral rebound was associated with a preferential depletion of CD4(+) T cells within the gastrointestinal tract. Though safe, the use of MAbs generally delayed, but did not prevent, virologic rebound. Consideration should be given to further pilot studies with alternative combinations of MAbs and perhaps additional novel treatment modalities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available